What's Love Got to Do with It? Explaining Adherence to Oral Antiretroviral Pre-exposure Prophylaxis for HIV-serodiscordant Couples
Overview
Authors
Affiliations
Objective: Adherence may be the "Achilles heel" of pre-exposure prophylaxis (PrEP), a promising biomedical approach to HIV prevention. This article presents an explanation of PrEP adherence for African serodiscordant couples derived from qualitative data.
Design: Explaining quantitative findings is one way qualitative investigation contributes to research in medicine and public health. This qualitative interview study was nested in the Partners PrEP Study, a phase III randomized trial evaluating oral tenofovir and emtricitabine/tenofovir PrEP to prevent HIV acquisition by HIV-uninfected partners in serodiscordant heterosexual couples.
Methods: In-depth qualitative interviews were provided by 60 Partners PrEP Study participants in Uganda. Interviews used open-ended questions eliciting information on adherence experiences, barriers, and facilitators. An inductive approach informed by grounded theory methodology was used to analyze study data.
Results: The proposed explanation may be summarized as follows. Serodiscordance destabilizes couples, as the HIV-negative partner reacts with anger, fear, and sadness to the implication of infidelity represented by HIV infection. A "discordance dilemma" ensues, as the desire to avoid acquiring HIV and the advantages of preserving the relationship become competing priorities. PrEP is seen as a solution-a means of safeguarding health without ending the relationship. PrEP users benefit from the support of partners, who reinforce adherence. Where discord in the relationship persists, adherence suffers.
Conclusions: PrEP adherence in serodiscordant couples may be understood as a function of the desire to reduce risk although preserving a partnered relationship. PrEP use in stable couples may be associated with improved adherence and thus, greater effectiveness.
Gichane M, Velloza J, Hosek S, Beauchamp G, Anderson P, Delany-Moretlwe S AIDS Behav. 2024; 29(2):527-534.
PMID: 39446266 PMC: 11814051. DOI: 10.1007/s10461-024-04536-3.
Preferences for oral and injectable PrEP among qualitative sub-study participants in HPTN 084.
Tolley E, Bula A, Chitukuta M, Ndimande-Khoza N, Etima J, Namey E PLoS One. 2024; 19(10):e0309811.
PMID: 39441777 PMC: 11498703. DOI: 10.1371/journal.pone.0309811.
Shah P, Spinelli M, Irungu E, Kabuti R, Ngurukiri P, Babu H AIDS Behav. 2024; 28(11):3836-3849.
PMID: 39136824 PMC: 11471708. DOI: 10.1007/s10461-024-04455-3.
Chebet J, Akyoo W, Goymann H, Harling G, Barnhart D, Mosha I PLoS One. 2024; 19(6):e0304077.
PMID: 38935796 PMC: 11210872. DOI: 10.1371/journal.pone.0304077.
Wyatt M, Pisarski E, Nalumansi A, Kasiita V, Kamusiime B, Nalukwago G PLOS Glob Public Health. 2024; 4(3):e0002916.
PMID: 38452111 PMC: 10919847. DOI: 10.1371/journal.pgph.0002916.